The Legal and Ethical Debate on Human Heritable Genome Editing (HHGE) in South Africa
By Jantina de Vries,
EthicsLab
| 11. 15. 2024
The conversation around human heritable genome editing (HHGE) in South Africa is marked by controversy and conflicting interpretations of the law. At the center of this debate lies a team of lawyers based at a South African university, who have long championed a highly liberal stance toward reproductive technologies, including HHGE. Their assertions, however, have raised significant concerns among South Africa’s legal, ethical, and scientific communities.
Is heritable human genome editing already legal in South Africa?
This team has made the controversial claim that HHGE is already legal in South Africa – a position that has gained significant national and international outrage in recent days. As a non-lawyer, I have struggled to make sense of their argument which seems highly technical. Let me try to explain what I think they are saying.
Their argument seems to hinge on a specific interpretation of the National Health Act, which prohibits genetic modification for the purposes of reproductive cloning. They seem to argue that the term "reproductive" in the law should be read to refer to the purpose of the genetic manipulation –...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
By Staff, The Medicine Maker | 03.21.2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later...